Proteomic analysis of HCV cirrhosis and HCV-induced HCC: Identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation

Transplantation

Volumn 87, Issue 1, 2009, Pages 143-152

  Mas, Valeria R ^a,b,d   Maluf, Daniel G ^a   Archer, Kellie J ^b,c   Yanek, Kenneth ^a   Bornstein, Karen ^a   Fisher, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Biomarkers; Hepatitis C virus; Hepatocellular carcinoma; Proteomics

Indexed keywords

PEPTIDE; TRANSFERRIN; BIOLOGICAL MARKER;

AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CELL ADHESION; CELL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; GENE CONTROL; GENETIC TRANSCRIPTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; CANCER STAGING; CHICKEN; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHICKENS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PROTEOMICS; TRANSFERRIN;

EID: 58949103709     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318191c68d     Document Type: Article

References (46)

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S.
2. Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver diseases in the United States: Summary of a workshop. Hepatology 2002; 36: 227.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745.
4. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74.
5. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35: S86.
6. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review. Hepatology 2002; 36: S84.
7. Sherman M. α-Fetoprotein: An obituary. J Hepatol 2001; 34: 603.
8. Daniele B, Bencivenga A, Megna AS, et al. α Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: S108.
9. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum a-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol 2005; 43: 434.
10. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogen-esis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001; 98: 15089.
11. Chung EJ, Sung YK, FarooqM, et al. Gene expression profile analysis in human hepatocellular carcinoma bycDNA microarray. Mol Cells 2002; 14: 382.
12. Kim JW, Wang XW. Gene expression profiling of preneoplastic liver disease and liver cancer: A new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 2003; 24: 363.
13. Mas VR, Maluf DG, Archer KJ, et al. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 2007; 84: 1262.
14. American Liver Tumor Study Group. Arandomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. Investigators Booklet and protocol 1998. United Network for Organ Sharing. Policy 3.6.4.4, 1998.
15. Hale JE, Butler JP, Gelfanova V, et al. A simplified procedure for the reduction and alkylation of cyteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal Biochem 2004; 333: 174.
16. Higgs RE, Knierman MD, GelfanovaV,et al. Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res 2005; 4: 1442.
17. Higgs RE, Knierman MD, Freeman AB, et al. Estimating statistical significance of peptide identifications from shotgun proteomics experiments. J Proteome Res 2007; 4: 1758.
18. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185.
19. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431.
20. Bell AW. Lipid metabolismin liver and selected tissues andin the whole body of ruminant animals. Prog Lipid Res 1979; 18: 117.
21. Tietge UJ, Boker KH, Bahr MJ, et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998; 45: 2255.
22. Eisenberg S, Levy RI. Lipoprotein metabolism. Adv Lipid Res 1975; 13: 1.
23. Sherlock S. Alcoholic liver disease. Lancet 1995; 345: 227.
24. Göbel T,Vorderwülbecke S,HauckK, et al. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006; 12: 7604.
25. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882.
26. Engwegen JY, Helgason HH, Cats A, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006; 12: 1536.
27. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 472.
28. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886.
29. Raz A, Meromsky L, Zvibel I, et al. Transformation-related changes in the expression of endogenous cell lectins. Int J Cancer 1997; 39: 353.
30. Gillenwater A, Xu XC, el-Nagger AK, et al. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996; 18: 422.
31. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998; 15: 3015.
32. Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin 3. Gastroenterology 1998; 115: 287.
33. Kondoh N, Wakatsuki T, Ryo A, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999; 59: 4990.
34. Rechreche H, Mallo GV, Montalto G, et al. Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer. Eur J Biochem 1997; 248: 225.
35. + T cells. Immunity 2002; 16: 779.
36. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172:2225.
37. Hisada M, Kamiya S, Fujita K, et al. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64: 1152.
38. Chiyo M, Shimozato O, Yu L, et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005; 115: 437.
39. + T cells. J Immunol 2004; 173: 7170.
40. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: Alterations that facilitate proliferation. Crit Rev Oncol/Hematol 2002; 42:65.
41. Lee AW, Oates PS, TrinderD. Effects of cell proliferation on the uptake of transferrin-bound iron by human hepatoma cells. Hepatology 2003; 38: 967.
42. Li L, Chen SH, Yu CH, et al. Identification of hepatocellular-carcinoma- associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res 2008; 7: 611.
43. El-Aneed A, Banoub J. Proteomics in the diagnosis of hepatocellular carcinoma: Focusonhigh risk hepatitisBandCpatients. Anticancer Res 2006; 26: 3293.
44. Takashima M, Kuramitsu Y, Yokoyama Y, et al. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics 2006; 6: 3894.
45. Sun S, Lee NP, Poon RT, et al. Oncoproteomics of hepatocellular carcinoma: From cancer markers' discovery to functional pathways. Liver Int 2007; 27: 1021.
46. SantamaríaE,Muñoz J,Fernández-IrigoyenJ, et al. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int 2007; 27: 163.